Overview

Drug-Drug Interaction (DDI) Study for TD-9855

Status:
Completed
Trial end date:
2018-04-21
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.
Phase:
Phase 1
Details
Lead Sponsor:
Theravance Biopharma
Treatments:
Caffeine
Fluvoxamine
Hydroxyitraconazole
Itraconazole